Published in Biochim Biophys Acta on September 01, 2009
Neurology of inherited glycosylation disorders. Lancet Neurol (2012) 1.82
A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency. Mol Biol Cell (2012) 0.99
Metabolic manipulation of glycosylation disorders in humans and animal models. Semin Cell Dev Biol (2010) 0.96
Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis (2011) 0.95
Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem (2011) 0.89
Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid. J Biol Chem (2010) 0.88
A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation. Dis Model Mech (2012) 0.86
Evolutionary history and functional diversification of phosphomannomutase genes. J Mol Evol (2010) 0.76
Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation. Glycoconj J (2016) 0.76
Sialic acids attached to N- and O-glycans within the Nav1.4 D1S5-S6 linker contribute to channel gating. Biochim Biophys Acta (2014) 0.75
Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG). Mol Cell Proteomics (2016) 0.75
A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2. Hum Mol Genet (2016) 0.75
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 10.70
AMPK and PPARdelta agonists are exercise mimetics. Cell (2008) 6.39
Production and purification of lentiviral vectors. Nat Protoc (2006) 6.01
Genetic defects in the human glycome. Nat Rev Genet (2006) 3.59
Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest (1998) 3.32
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes (2000) 2.39
Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet (2007) 2.12
The yeast SEC53 gene encodes phosphomannomutase. J Biol Chem (1988) 1.87
Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis (2004) 1.86
Cell penetrating peptides in drug delivery. Pharm Res (2004) 1.86
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet (2006) 1.65
The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant (2008) 1.60
Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance. Pediatr Res (1996) 1.41
[Treatment prospects of lysosomal storage disorders]. Orv Hetil (2008) 1.40
On the nomenclature of congenital disorders of glycosylation (CDG). J Inherit Metab Dis (2008) 1.38
Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest (1996) 1.38
The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution. Nat Struct Biol (1996) 1.27
The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem (2006) 1.22
Studies on phosphomannose isomerase. II. Characterization as a zinc metalloenzyme. J Biol Chem (1968) 1.19
Abnormal synthesis of mannose 1-phosphate derived carbohydrates in carbohydrate-deficient glycoprotein syndrome type I fibroblasts with phosphomannomutase deficiency. Glycobiology (1998) 1.16
Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality. J Biol Chem (2005) 1.16
Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality. Mol Cell Biol (2006) 1.15
Zebrafish fat-free is required for intestinal lipid absorption and Golgi apparatus structure. Cell Metab (2006) 1.12
Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Glycobiology (2005) 1.12
Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration. Am J Physiol Endocrinol Metab (2004) 1.10
Translation attenuation by PERK balances ER glycoprotein synthesis with lipid-linked oligosaccharide flux. J Cell Biol (2007) 1.09
Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: implications for extracellular glucose and intracellular mannose 6-phosphate. J Biol Chem (2005) 1.08
Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes. Biochem J (1999) 1.08
Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway. J Biol Chem (2007) 1.07
Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Brain (2008) 1.07
High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet (2001) 1.06
Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur J Pediatr (1998) 1.03
Congenital disorders of N-glycosylation including diseases associated with O- as well as N-glycosylation defects. Pediatr Res (2006) 1.02
Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse. Biochim Biophys Acta (2001) 1.02
Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr (1998) 1.01
Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr (2002) 1.01
Carbohydrate-deficient glycoprotein syndrome type 1: correction of the glycosylation defect by deprivation of glucose or supplementation of mannose. Glycoconj J (1998) 1.01
The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development. Mol Cell Biol (2006) 0.95
Stimulation of N-linked glycosylation and lipid-linked oligosaccharide synthesis by stress responses in metazoan cells. Crit Rev Biochem Mol Biol (2006) 0.94
Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia. J Inherit Metab Dis (2002) 0.93
Treatment of Crigler-Najjar Syndrome type 1 by hepatic progenitor cell transplantation: a simple procedure for management of hyperbilirubinemia. Transplant Proc (2008) 0.93
Activation of glycogen phosphorylase with 5-aminoimidazole-4-carboxamide riboside (AICAR). Assessment of glycogen as a precursor of mannosyl residues in glycoconjugates. J Biol Chem (2004) 0.91
Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi (2008) 0.91
Direct utilization of mannose for mammalian glycoprotein biosynthesis. Glycobiology (1998) 0.90
A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency. Hum Mol Genet (2002) 0.90
Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with Congenital Disorders of Glycosylation (CDG). Glycobiology (2000) 0.89
Serum and glucocorticoid-regulated kinase Sgk1 inhibits insulin-dependent activation of phosphomannomutase 2 in transfected COS-7 cells. Am J Physiol Cell Physiol (2004) 0.88
Glycogen: a carbohydrate source for GLUT-1 glycosylation during glucose deprivation of 3T3-L1 adipocytes. Am J Physiol (1996) 0.88
Membrane-permeant derivatives of mannose-1-phosphate. Bioorg Med Chem (2002) 0.86
Metformin-stimulated mannose transport in dermal fibroblasts. J Biol Chem (2003) 0.86
Exploring structure-activity relationships around the phosphomannose isomerase inhibitor AF14049 via combinatorial synthesis. Bioorg Med Chem Lett (1998) 0.82
Exogenous mannose does not raise steady state mannose-6-phosphate pools of normal or N-glycosylation-deficient human fibroblasts. Mol Genet Metab (2009) 0.82
Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-bisphosphatase. J Biol Chem (2008) 0.82
Treatment of lysosomal storage disorders: focus on the neuronal ceroid-lipofuscinoses. Acta Neurobiol Exp (Wars) (2008) 0.81
Role of serum- and glucocorticoid-inducible kinase SGK1 in glucocorticoid regulation of renal electrolyte excretion and blood pressure. Kidney Blood Press Res (2008) 0.81
Mono, di and tri-mannopyranosyl phosphates as mannose-1-phosphate prodrugs for potential CDG-Ia therapy. Bioorg Med Chem Lett (2006) 0.80
Underdiagnosis of mild congenital disorders of glycosylation type Ia. Pediatr Neurol (2005) 0.80
Stem cell therapy for inherited metabolic disorders of the liver. Exp Hematol (2008) 0.79
Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology. EMBO Rep (2008) 0.79
Congenital disorders of glycosylation: rapidly enlarging group of (neuro)metabolic disorders. Early Hum Dev (2007) 0.76
Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). J Inherit Metab Dis (2006) 0.76
Congenital disorder of glycosylation type Ia in a 6-year-old girl with a mild intellectual phenotype: two novel PMM2 mutations. J Inherit Metab Dis (2005) 0.76
Congenital disorder of glycosylation type Ia revealed by hypertransaminasemia and failure to thrive in a young boy with normal neurodevelopment. J Pediatr Gastroenterol Nutr (2005) 0.76